A SpringMed Kiadó könyveit 20% kedvezménnyel megvásárolhatja a kiadónál!
Vagy megrendelheti honlapunkon, telefonon, faxon, illetve levélben!
Várjuk kérdéseit, észrevételeit!

Könyvajánlók

Tudatosan az egészségért (CD)

Hogyan szokjunk le a dohányzásról?

Cukorbetegek nagy diétáskönyve

Amit a szénanátháról tudni kell

Szerzők:

• Arshad, S Hasan
• Babu, K.Suresh
• Holgate, Stephen T.

Kiadás:

Kiadó: Martin Dunitz
ISBN 1841840904
2001

Könyvajánlók ebben a kategóriában

Kérjük válasszon tartalmat:

Fülszöveg

Preface

The discovery by Prausnitz and KOstner in 1921 of reagin, the circulating substance that could passively transfer the immediate allergic response from one individual to another, stimulated a 50-year search for the molecular basis of this phenomenon.The identification of reagin as IgE independently by Ishizakas and Johansson in the late 1960s provided the rational basis for diseases such as rhinitis, asthma and food allergy and a legitimate target for novel therapeutics. Almost 25 years were to pass before it was clearly shown that a monoclonal antibody directed against that part of the IgE molecule that is encrypted by the high  and low affinity IgE receptors on effector cells could dramatically remove circulating and tissue IgE by forming small complexes that are easily cleared without cross linking IgE on the surface of effector cells and, therefore, failing to produce anaphylactic responses. The fully humanized monoclonal antibody omalizumab (Xolair TM ) has these properties. It has been clearly demonstrated that when administered at 2-4 weekly intervals this therapy has markedly beneficial effects on multiple outcome measures in allergic asthma.

This pocketbook provides an illustrative summary of the role of IgE in asthma and allied allergic disorders and the effects of anti-IgE treatment. With little new having been introduced into the armamentarium for asthma therapy in the last three decades other than improvements in ß2 adrenoceptor agonists, corticosteroids and cysteinyl leukotriene antagonists, the introduction of omalizurmab is likely to provide a new way of treating allergic disorders with effects that extend beyond a single affected organ and tissue. Its precise role in treatment guidelines will need to be carefully evaluated, but its clear efficacy and safety provide a clear statement about the importance of IgE across the full spectrum of allergic disease.